M Kyle Hadden (Kyle Hadden)

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 14

Top Topics

Signaling Pathway

Small Cell Lung Cancer

Top Venues

Proceedings of the National Academy of Sciences of the United States of America

Expert opinion on drug discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Marcello Stanzione, Jun Zhong, Edmond Wong, Thomas J LaSalle, Jillian F Wise, Antoine Simoneau, David T Myers, Sarah Phat, Moshe Sade-Feldman, Michael S Lawrence, M Kyle Hadden, Lee Zou, Anna F Farago, Nicholas J Dyson, Benjamin J Drapkin
Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer. Science advances 8 (19) (2022)
Christopher O Dusek, Radha Charan Dash, Kerry S McPherson, Jackson T Calhoun, Irina Bezsonova, Dmitry M Korzhnev, M Kyle Hadden
DNA Sequence Specificity Reveals a Role of the HLTF HIRAN Domain in the Recognition of Trinucleotide Repeats. Biochemistry (2022)
Kewa Jiang, Jiyang Zhang, Yuping Huang, Yingzheng Wang, Shuo Xiao, M Kyle Hadden, Teresa K Woodruff, Jianjun Sun
A platform utilizing Drosophila ovulation for nonhormonal contraceptive screening. Proceedings of the National Academy of Sciences of the United States of America 118 (28) (2021)
Radha Charan Dash, M Kyle Hadden
Protein-Protein Interactions in Translesion Synthesis. Molecules (Basel, Switzerland) 26 (18) (2021)
Kanayo E Ikeh, Erica N Lamkin, Andrew Crompton, Jamie Deutsch, Kira J Fisher, Mark E Gray, David J Argyle, Won Y Lim, Dmitry M Korzhnev, M Kyle Hadden, Jiyong Hong, Pei Zhou, Nimrat Chatterjee
REV1 Inhibition Enhances Radioresistance and Autophagy. Cancers 13 (21) (2021)
Kerry Silva McPherson, Angela M Zaino, Radha C Dash, Alessandro A Rizzo, Yunfeng Li, Bing Hao, Irina Bezsonova, M Kyle Hadden, Dmitry M Korzhnev
Structure-Based Drug Design of Phenazopyridine Derivatives as Inhibitors of Rev1 Interactions in Translesion Synthesis. ChemMedChem 16 (7) (2021)
Christopher O Dusek, M Kyle Hadden
Targeting the GLI family of transcription factors for the development of anti-cancer drugs. Expert opinion on drug discovery 16 (3) (2020)
Seema M Patel, Radha Charan Dash, M Kyle Hadden
Translesion synthesis inhibitors as a new class of cancer chemotherapeutics. Expert opinion on investigational drugs 30 (1) (2020)
Jennifer R Pace, Kelly A Teske, Lianne Q Chau, Radha Charan Dash, Angela M Zaino, Robert J Wechsler-Reya, M Kyle Hadden
Structure-Activity Relationships for Itraconazole-Based Triazolone Analogues as Hedgehog Pathway Inhibitors. Journal of medicinal chemistry 62 (8) (2019)
Radha C Dash, Zuleyha Ozen, Kaitlyn R McCarthy, Nimrat Chatterjee, Cynthia A Harris, Alessandro A Rizzo, Graham C Walker, Dmitry M Korzhnev, M Kyle Hadden
Virtual Pharmacophore Screening Identifies Small-Molecule Inhibitors of the Rev1-CT/RIR Protein-Protein Interaction. ChemMedChem 14 (17) (2019)
Evrett N Thompson, Vibhavari Sail, Daniel S Raccuia, M Kyle Hadden
Probing seco-steroid inhibition of the hedgehog signaling pathway. Molecular and cellular biochemistry 450 (1-2) (2018)
Jiachen Wen, M Kyle Hadden
Structure-Activity Relationship Studies of Vitamin D3 Analogues Containing an Ether or Thioether Linker as Hedgehog Pathway Inhibitors. ChemMedChem 13 (7) (2018)
Radha Charan Dash, Zuleyha Ozen, Alessandro A Rizzo, Socheata Lim, Dmitry M Korzhnev, M Kyle Hadden
Structural Approach To Identify a Lead Scaffold That Targets the Translesion Synthesis Polymerase Rev1. Journal of chemical information and modeling 58 (11) (2018)
Vibhavari Sail, Alessandro A Rizzo, Nimrat Chatterjee, Radha C Dash, Zuleyha Ozen, Graham C Walker, Dmitry M Korzhnev, M Kyle Hadden
Identification of Small Molecule Translesion Synthesis Inhibitors That Target the Rev1-CT/RIR Protein-Protein Interaction. ACS chemical biology 12 (7) (2017)